PsO Far, PsO Good for Can-Fite’s Oral A3 Adenosine Receptor Agonist
Oral piclidenoson continues to show efficacy and safety in psoriasis, according to the first Phase 3 data which appears in the Journal of the European Academy of Dermatology and Venereology. Can-Fite’s piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug that has shown efficacy in Phase II and III psoriasis […]